Skip to main content
Cerezyme® (imiglucerase) for injection logo

Cerezyme® (imiglucerase) Dosing and Administration


Cerezyme dosing can be individualized for each patient.1

Recommended Cerezyme dosing and administration

Cerezyme is administered as an intravenous infusion over 1 to 2 hours1

  • Ensure physicians knowledgeable in the management of patients with Gaucher disease direct therapy with CEREZYME
  • The recommended dosage of Cerezyme ranges from 2.5 units/kg 3 times a week to 60 units/kg once every 2 weeks
  • For patients weighing greater than 20 kg, infuse the diluted Cerezyme solution over 1 to 2 hours. For patients weighing 20 kg or less, infuse the diluted Cerezyme solution over 2 hours
  • Titrate the dosage based on disease severity and therapeutic goals for the patient
  • Initiate Cerezyme in a healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation equipment
  • If a severe hypersensitivity reaction or a severe infusion-associated reaction (IAR) occurs, discontinue Cerezyme treatment and initiate appropriate medical treatment
  • If a mild or moderate hypersensitivity reaction or a mild or moderate IAR occurs, consider decreasing the infusion rate, temporarily stopping the infusion, and/or administering antihistamines, antipyretics, and/or corticosteroids
  • For patients who experience a hypersensitivity reaction to Cerezyme and a decision is made to readminister the product, consider reducing the rate of infusion and pretreat with antihistamines and/or corticosteroids. Monitor patients for the occurrence of new hypersensitivity reactions

How to prepare and administer Cerezyme1

Reconstitute each vial of Cerezyme by slowly injecting 10.2 mL of Sterile Water for Injection, USP, down the inside wall of each vial

Roll and tilt the vial to allow the powder to dissolve completely. Visually inspect the solution after reconstitution for particulate matter and discoloration. Discard if opaque particles or discoloration are observed. After reconstitution, each vial will yield Cerezyme at a concentration of 40 units/mL

Withdraw the required volume of Cerezyme from the vial(s)

Dilute the Cerezyme solution for infusion promptly with 0.9% Sodium Chloride Injection, USP, to a final volume that is calculated based on prescribed dose

Total infusion volumes and infusion time for Cerezyme 

Patient weightTotal infusion volumeaInfusion timeMaximum infusion rate
1.5 kg to <6 kg12 mL (in a syringe)2 hours6 mL/hour
6 kg to <13 kg26 mL (in a syringe)2 hours13 mL/hour
13 kg to ≤20 kg100 mL (infusion bag)2 hours50 mL/hour
>20 kg to ≤100 kg200 mL (infusion bag)1 to 2 hours200 mL/hour
>100 kg400 mL (infusion bag)1 to 2 hours400 mL/hour

aFinal concentration of diluted Cerezyme solution is between 6 units/mL and 30 units/mL.

If Cerezyme is prescribed at a dose lower than 60 units/kg:

  • Dilute the required total units of reconstituted Cerezyme (at a concentration of 40 units/mL) with 0.9% Sodium Chloride Injection to a final concentration between 6 units/mL and 30 units/mL
  • If the determined dose of Cerezyme translates into a total volume of 26 mL or less, administer using a syringe for infusion via a syringe pump

For accuracy of dilution, if less than 2 mL of reconstituted Cerezyme (40 units/mL) is needed for the preparation of the determined dose:

  • Prepare a larger final volume of Cerezyme for infusion initially maintaining the final concentration of the diluted Cerezyme solution between 6 units/mL to 30 units/mL
  • Subsequently, discard the excess volume and administer only the volume of Cerezyme solution corresponding to the prescribed dose

Gently invert the syringe for infusion or the infusion bag to mix the solution. Throughout Cerezyme preparation, avoid vigorous shaking, agitation, and foaming

Visually inspect the solution prior to administration of the final product for particulate matter and discoloration. Slight flocculation of protein particles (described as thin translucent fibers) may occur after dilution and does not affect the quality of the product

Administer Cerezyme as an intravenous infusion with a 0.2 micron in-line low protein-binding filter

Download the Cerezyme Reconstitution & Administration Guide for detailed guidance on preparation and administration.

Storing Cerezyme1

  • Cerezyme for injection is supplied as a white to off-white lyophilized powder in a single-dose vial: NDC 58468‑4663‑1
  • Cerezyme vials should be stored refrigerated at 2 °C to 8 °C (36 °F to 46 °F)
  • Once diluted, the solution can be stored at 2 °C to 8 °C (36 °F to 46 °F) for up to 24 hours
  • Once reconstituted, the solution can be refrigerated at 2 °C to 8 °C (36 °F to 46 °F) or stored at room temperature at 20 °C to 25 °C (68 °F to 77 °F) for up to 12 hours
Checkmark icon

An established ERT for children

Studied in the largest reported group of pediatric patients

Badge icon representing 30 years

The only ERT with multiple studies showing long-term outcomes

When an ERT is needed, choose the longest-approved therapy

Indication

Cerezyme® (imiglucerase) for injection is indicated for the treatment of non-central nervous system (CNS) manifestations of Type 1 or Type 3 Gaucher disease in adult and pediatric patients. 

Important Safety Information

WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS
Patients treated with enzyme replacement therapies have experienced life-threatening hypersensitivity reactions, including anaphylaxis. Anaphylaxis has occurred during the early course of enzyme replacement therapy and after extended duration of therapy. Initiate CEREZYME in a healthcare setting with appropriate medical monitoring and support measures, including cardiopulmonary resuscitation equipment. If a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, discontinue CEREZYME immediately, and initiate appropriate medical treatment, including use of epinephrine. Inform patients of the symptoms of life-threatening hypersensitivity reactions, including anaphylaxis, and to seek immediate medical care should symptoms occur.

Warnings and Precautions:

Hypersensitivity Reactions Including Anaphylaxis: See Boxed WARNING.
Patients with antibody to imiglucerase have a higher risk of hypersensitivity reactions. Consider periodic monitoring during the first year of treatment for IgG antibody formation.

Consider risks and benefits of readministering Cerezyme to individual patients following a severe reaction. If a mild or moderate hypersensitivity reaction occurs, consider reducing the rate of infusion, pretreat with antihistamines and/or corticosteroids, and monitor patients for new signs and symptoms of a hypersensitivity reaction. 

Infusion-Associated Reactions:
Infusion associated reactions (IARs) have been observed in patients treated with Cerezyme. If a severe IAR occurs, discontinue CEREZYME and immediately initiate appropriate medical treatment. Consider the risks and benefits of re-administering CEREZYME following a severe IAR. If a mild or moderate IAR occurs, consider decreasing the infusion rate, temporarily stopping the infusion, and/or administering antihistamines, antipyretics, and/or corticosteroids.

Adverse Reactions:

  • Adverse reactions reported in adults and pediatric patients include back pain, chills, dizziness, fatigue, headache, hypersensitivity reactions, nausea, pyrexia, and vomiting. 

Please see accompanying Full Prescribing Information, including Boxed WARNING.

Indication

Important Safety Information

Reference: 1. Cerezyme (imiglucerase). Prescribing information. Genzyme Corporation, Cambridge, MA.

©2026 Sanofi. All rights reserved. Cerezyme and Sanofi are registered trademarks of Sanofi or an affiliate. CareConnect is a trademark of Sanofi or an affiliate. MAT-US-2015543-v4.0-01/2026